Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green Sells 292 Shares

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 292 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $35.76, for a total value of $10,441.92. Following the completion of the sale, the senior vice president now owns 127,603 shares in the company, valued at approximately $4,563,083.28. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Paula Green also recently made the following trade(s):

• On Wednesday, May 21st, Paula Green sold 632 shares of Twist Bioscience stock. The shares were sold at an average price of $29.75, for a total transaction of $18,802.00.
• On Monday, May 5th, Paula Green sold 1,101 shares of Twist Bioscience stock. The shares were sold at an average price of $37.65, for a total value of $41,452.65.
• On Wednesday, April 2nd, Paula Green sold 140 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total value of $5,422.20.

Twist Bioscience Stock Down 3.1%

Shares of TWST traded down $1.14 during midday trading on Friday, hitting $35.80. 788,445 shares of the company's stock traded hands, compared to its average volume of 973,280. The company has a current ratio of 4.51, a quick ratio of 4.24 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of -11.03 and a beta of 2.38. Twist Bioscience Corporation has a 1 year low of $27.12 and a 1 year high of $60.90. The firm's fifty day moving average is $33.55 and its 200-day moving average is $40.69.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. As a group, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on TWST. JPMorgan Chase & Co. lowered their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Guggenheim reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Barclays dropped their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group lowered their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Finally, Robert W. Baird cut their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $50.40.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of TWST. Farther Finance Advisors LLC raised its position in Twist Bioscience by 18.5% during the 1st quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company's stock worth $251,000 after buying an additional 1,006 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Twist Bioscience by 6,499.1% during the 1st quarter. GAMMA Investing LLC now owns 29,366 shares of the company's stock valued at $1,153,000 after buying an additional 28,921 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Twist Bioscience in the first quarter valued at about $893,000. Vanguard Group Inc. increased its stake in Twist Bioscience by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after buying an additional 189,791 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Twist Bioscience by 34.5% during the fourth quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock worth $1,761,000 after purchasing an additional 9,722 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.